Supernus Pharmaceuticals PE Ratio 2011-2024 | SUPN

Current and historical p/e ratio for Supernus Pharmaceuticals (SUPN) from 2011 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Supernus Pharmaceuticals PE ratio as of November 20, 2024 is 26.71.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Supernus Pharmaceuticals PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2024-11-19 35.53 33.21
2024-09-30 31.18 $1.07 29.14
2024-06-30 26.75 $0.09 297.22
2024-03-31 34.11 $-0.29 0.00
2023-12-31 28.94 $-0.00 0.00
2023-09-30 27.57 $0.41 67.24
2023-06-30 30.06 $0.73 41.18
2023-03-31 36.23 $0.89 40.71
2022-12-31 35.67 $1.03 34.63
2022-09-30 33.85 $0.64 52.89
2022-06-30 28.92 $1.01 28.63
2022-03-31 32.32 $1.30 24.86
2021-12-31 29.16 $0.98 29.76
2021-09-30 26.67 $1.51 17.66
2021-06-30 30.79 $1.85 16.64
2021-03-31 26.18 $2.07 12.65
2020-12-31 25.16 $2.36 10.66
2020-09-30 20.84 $2.41 8.65
2020-06-30 23.75 $2.21 10.75
2020-03-31 17.99 $2.17 8.29
2019-12-31 23.72 $2.11 11.24
2019-09-30 27.48 $1.97 13.95
2019-06-30 33.09 $1.95 16.97
2019-03-31 35.04 $1.91 18.35
2018-12-31 33.22 $2.06 16.13
2018-09-30 50.35 $1.84 27.36
2018-06-30 59.85 $1.61 37.17
2018-03-31 45.80 $1.36 33.68
2017-12-31 39.85 $1.06 37.59
2017-09-30 40.00 $1.06 37.74
2017-06-30 43.10 $1.95 22.10
2017-03-31 31.30 $1.81 17.29
2016-12-31 25.25 $1.70 14.85
2016-09-30 24.73 $1.58 15.65
2016-06-30 20.37 $0.48 42.44
2016-03-31 15.25 $0.33 46.21
2015-12-31 13.44 $0.27 49.78
2015-09-30 14.03 $0.23 61.00
2015-06-30 16.98 $0.54 31.44
2015-03-31 12.09 $0.59 20.49
2014-12-31 8.30 $0.19 43.68
2014-09-30 8.69 $-0.56 0.00
2014-06-30 10.95 $-1.73 0.00
2014-03-31 8.94 $-2.70 0.00
2013-12-31 7.54 $-2.92 0.00
2013-09-30 7.33 $-2.78 0.00
2013-06-30 6.43 $-2.55 0.00
2013-03-31 5.62 $-2.27 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.962B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00